Skip to content

Study · Animal study (in vivo) · rat · 2004

1 result

The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system.

Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Kamenskii AA, Myasoedov NF

Neuroscience and behavioral physiology1 May 2004Cited by 8 (Europe PMC)

PMID15341218 (opens in a new tab)DOI10.1023/b:neab.0000018752.59465.28 (opens in a new tab)PepBankPUB-15341218
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with MPTP-induced dopaminergic lesions, daily intranasal Semax decreased the severity of behavioral disturbances.

    In plain wordsIn rats with brain damage caused by MPTP, daily Semax given through the nose reduced the severity of behaviour problems.

    Peptide
    Semax
    Outcome
    DecreaseMPTP-induced behavioral disturbances
    Study

    ratn: not reported in source

    MPTP-induced lesions of the brain dopaminergic system
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    0.2 mg/kg · intranasalAs given in this study (rat).

    Source sentences

    Summary
    Daily intranasal administration of Semax at a dose of 0.2 mg/kg decreased the severity of MPTP-induced behavioral disturbances.
    2 context sentences
    Summary · context
    This report describes studies cf the effects of the ACTH(4-10) analog Semax (MEHFPGP) on the behavior of white rats with lesions to the brain dopaminergic system induced by the neurotoxin MPTP.
    Summary · context
    Neurotoxin injections were shown to decrease movement activity and increase anxiety in the animals.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.